Luminary Group

Thank you, Umbrex, for recognizing Luminary Group as one of the Top Pharmaceutical Consulting Firms! Umbrex has thoughtfully compiled this list based on extensive industry experience, discussions with industry leaders, and comprehensive secondary research. These leading consulting firms specialize in various sectors of the pharmaceutical industry, including clinical development, digital health innovation, pharmacovigilance, strategic planning, market access, product lifecycle management, and supply chain and manufacturing. Many also bring expertise in regulatory compliance and Health Economics and Outcomes Research (HEOR). Notably, many Umbrex consultants have prior experience working with most of the firms highlighted on this list. https://lnkd.in/eHeptiWE

𝗔𝗻𝗱𝗿𝗼𝗺𝗲𝗱𝗮 𝗦𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗿𝗼𝗯𝗼𝘁-𝗮𝘀𝘀𝗶𝘀𝘁𝗲𝗱 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗽𝗿𝗼𝗰𝗲𝗱𝘂𝗿𝗲𝘀 Andromeda Surgical announced that a surgeon in Chile performed a robotic-assisted holmium laser enucleation of the prostate (HoLEP) with its platform. https://lnkd.in/gyMATrUC

𝗧𝗿𝗮𝗰𝗲𝗿 𝗕𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟬𝗠, 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝘄𝗶𝘁𝗵 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 Tracer Biotechnologies has raised a $10 million Series A round to advance its technology that’s designed to monitor circulating tumor DNA in cancer patients over … https://lnkd.in/djkHFmV2

𝗢𝘂𝗿𝗮 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟮𝟬𝟬𝗠 𝗳𝗿𝗼𝗺 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗗𝗲𝘅𝗰𝗼𝗺 ŌURA announced today that it completed a $200 million Series D funding round that included Dexcom https://lnkd.in/dgMebAWh

𝗔𝘅𝗼𝗳𝘁 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗵𝘂𝗺𝗮𝗻 𝘀𝘁𝘂𝗱𝘆 𝗼𝗳 𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝗕𝗖𝗜𝘀 Axoft announced today that it received approval to conduct a first-in-human study for its novel soft materials for brain-computer interfaces (BCIs). https://lnkd.in/dKS65qvY

𝗨𝗻𝘃𝗲𝗹𝗹𝗶𝗻𝗴 𝗥𝗲𝗰𝗲𝗻𝘁 𝗙𝘂𝗻𝗱𝗶𝗻𝗴,𝗠&𝗔 𝗮𝗻𝗱 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀- 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 Roche acquires Poseida Therapeutics, Inc. for up to $1.5B, expanding into CAR-T therapies. Arrowhead Pharmaceuticals licenses muscle, CNS, and lung disease programs to Sarepta Therapeutics for $500M upfront and $325M in equity. Novo Holdings is expected to receive EU approval on December 6 for $16.5B acquisition of Catalent Pharma Solutions. PTC Therapeutics, Inc. sells Rare Pediatric Disease Priority Review Voucher for $150M after FDA approval of Kebilidi. Grifols seeks to refinance €1.4B in debt after Brookfield withdraws bid; prepares to present strategic plan to investors. AbbVie acquires Nimble Therapeutics for $200M, gaining oral IL-23 blocker to complement Skyrizi®. BeiGene pays $150M for CSPC’s MAT2A inhibitor, expanding its cancer combo pipeline. Chroma Medicine and Nvelop Therapeutics merge to combine epigenetic editing and non-viral delivery tech, raising $75M.K. ADC biotech Adcendo nabs $135M Series B as it enters the clinic. Eli Lilly and Company invests $3B in Wisconsin site, automating production for diabetes, obesity drugs, creating 750 skilled jobs.

𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 𝘁𝘂𝗿𝗻𝘀 𝘁𝗼 𝗕𝗶𝗼𝗔𝗴𝗲 𝗳𝗼𝗿 𝗻𝗲𝘄 𝘁𝗮𝗿𝗴𝗲𝘁𝘀 𝗯𝗮𝘀𝗲𝗱 𝗼𝗻 𝗹𝗼𝗻𝗴𝗲𝘃𝗶𝘁𝘆 𝗮𝗻𝗱 𝗲𝘅𝗲𝗿𝗰𝗶𝘀𝗲 BioAge Labs which began nearly a decade ago as an anti-aging biotech and then turned to obesity this year, is going back to its roots …Kristen Fortney https://lnkd.in/eTiSk7pK

𝗦𝗶𝘁𝗲𝗢𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, 𝗮 𝗽𝗮𝗶𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘁𝗵𝗮𝘁'𝘀 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝗲𝗱 𝘄𝗶𝘁𝗵 𝗩𝗲𝗿𝘁𝗲𝘅, 𝗻𝗮𝗯𝘀 $𝟭𝟬𝟬𝗠 About eight years after its Series B, a small biotech working on non-opioid treatments has raised its Series C to gather clinical proof of concept …John Mulcahy, Ph.D. SiteOne Therapeutics, Inc. https://lnkd.in/dmN67KQG

𝗝𝗮𝘇𝘇 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗖𝗘𝗢 𝗮𝗻𝗱 𝗰𝗼-𝗳𝗼𝘂𝗻𝗱𝗲𝗿 𝗕𝗿𝘂𝗰𝗲 𝗖𝗼𝘇𝗮𝗱𝗱 𝗶𝘀 𝗿𝗲𝘁𝗶𝗿𝗶𝗻𝗴 Jazz Pharmaceuticals CEO Bruce Cozadd is ready to play his outro. On Monday, Cozadd announced plans to retire, nearly 22 years … https://lnkd.in/dNPw5HGj

𝗕𝗶𝗼𝗩𝗮𝘅𝘆𝘀 𝗔𝗰𝗾𝘂𝗶𝗿𝗲𝘀 𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗟𝗶𝗽𝗶𝗱 𝗦𝘂𝗽𝗽𝗹𝘆 𝗳𝗼𝗿 𝗗𝗣𝗫 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 In anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, BioVaxys Technology Corp. has acquired a 48-kilogram supply of GMP-grade lipid to enable production of the Company's DPX antigen packaging delivery platform https://lnkd.in/dzdFdmcT